Weight gain on treatment: more evidence that TAF plus dolutegravir leads to greater gains
Study shows Biktarvy for PEP has fewer side effects and better completion rates
Better adherence to PrEP is associated with more bone loss
Large international study finds 40% higher risk of serious cardiovascular problems in people taking abacavir since 2012
Large US study confirms that people switching from TDF to TAF experience rising blood fat levels
Older version of tenofovir used as PrEP linked to weight loss
Most switches to Descovy PrEP are probably unnecessary and some may be harmful
People over 50 years old or with existing kidney dysfunction are more likely to get kidney damage when using tenofovir disoproxil-based PrEP
New predictors for peripheral neuropathy found in study of people living with HIV
